Ensysce Biosciences (ENSC) Gains from Investment Securities (2018 - 2021)

Ensysce Biosciences (ENSC) has reported Gains from Investment Securities for 4 consecutive years, with -$1.5 million the latest figure, recorded in Q3 2021.

• In Q3 2021, Gains from Investment Securities rose 62.02% year-over-year to -$1.5 million; the TTM figure through Dec 2021 stood at $2.5 million (up 229.55% YoY), while the FY2021 annual figure was $11.6 million, up 706.71% from the prior year.
• Gains from Investment Securities fell to -$1.5 million in Q3 2021 per ENSC's latest filing, from $1.5 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $2.5 million in Q4 2020 and bottomed at -$4.0 million in Q3 2020.
• Historically, Gains from Investment Securities has averaged -$33790.6 across 4 years, with a median of $136500.0 in 2019.
• Annual changes were most pronounced in 2019 — Gains from Investment Securities soared 204.35% — and 2020, when it sank 3023.63%.
• Ensysce Biosciences' Gains from Investment Securities stood at -$1.6 million in 2018, then jumped by 204.35% to $1.6 million in 2019, then soared by 52.87% to $2.5 million in 2020, then tumbled by 160.53% to -$1.5 million in 2021.
• Business Quant data shows ENSC's Gains from Investment Securities at -$1.5 million in Q3 2021, $1.5 million in Q1 2021, and $2.5 million in Q4 2020.